Next, islets were incubated for 1 h in 20 mmol/l glucose supplemented with agonists in the presence or absence of blockers
Things they had given up on, activities they assumed were permanently behind them, suddenly become possible again
A review of the evidence on their effects on hepatocellular carcinoma
[1] Healthcare providers may need to adjust the dosages of these concomitant medications to mitigate the risk of hypoglycemia
At ACR Convergence 2025, researchers from Toronto and NYU reported that PsA patients starting GLP-1 receptor agonists had significant improvements in joint counts, CRP, pain scores, and DAPSA disease activity scores within one year of treatment. Whats interesting is that you dont seem to need a large dose to see these benefits
The future may involve: Sequencing and Combination: Using agents with complementary mechanisms (e.g., an incretin for weight loss combined with a myostatin inhibitor for lean mass preservation)